Literature DB >> 10069556

Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking.

D T George1, R Rawlings, M J Eckardt, M J Phillips, S E Shoaf, M Linnoila.   

Abstract

Disturbances in central nervous system serotonin (5-HT) have been implicated in the pathophysiology of alcoholism. To test the hypothesis that increasing 5-HT function could promote treatment compliance, we randomized patients who had completed a 5-week inpatient treatment program for alcoholism to receive either buspirone or placebo for 1 year. Ten of the 49 patients remained in the study for the entire year. The days to relapse did not differ significantly between patients receiving buspirone or placebo. Regardless of the medication, late-onset alcoholics had a longer time to relapse than early-onset alcoholics. Cerebrospinal fluid showed that patients with high concentrations of both the 5-HT metabolite, 5-hydroxyindoleacetic acid, and the dopamine metabolite, homovanillic acid, were more likely to relapse, compared with patients with low concentrations of cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069556     DOI: 10.1111/j.1530-0277.1999.tb04110.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  9 in total

1.  A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.

Authors:  David H Overstreet; Darin J Knapp; Sheryl S Moy; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2003-04-04       Impact factor: 4.530

Review 2.  Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Association between Val66Met brain-derived neurotrophic factor (BDNF) gene polymorphism and post-treatment relapse in alcohol dependence.

Authors:  Marcin Wojnar; Kirk J Brower; Stephen Strobbe; Mark Ilgen; Halina Matsumoto; Izabela Nowosad; Elzbieta Sliwerska; Margit Burmeister
Journal:  Alcohol Clin Exp Res       Date:  2009-01-27       Impact factor: 3.455

4.  Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.

Authors:  John D Roache; Yanmei Wang; Nassima Ait-Daoud; Bankole A Johnson
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

5.  Counteracting incentive sensitization in severe alcohol dependence using deep brain stimulation of the nucleus accumbens: clinical and basic science aspects.

Authors:  Hans-Jochen Heinze; Marcus Heldmann; Jürgen Voges; Hermann Hinrichs; Josep Marco-Pallares; Jens-Max Hopf; Ulf J Müller; Imke Galazky; Volker Sturm; Bernard Bogerts; Thomas F Münte
Journal:  Front Hum Neurosci       Date:  2009-09-02       Impact factor: 3.169

Review 6.  Pharmacogenetic insights to monoaminergic dysfunction in alcohol dependence.

Authors:  Andreas Heinz; David Goldman; Jürgen Gallinat; Gunter Schumann; Imke Puls
Journal:  Psychopharmacology (Berl)       Date:  2004-05-18       Impact factor: 4.530

7.  Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.

Authors:  David H Overstreet; Darin J Knapp; George R Breese
Journal:  Alcohol Clin Exp Res       Date:  2007-07-11       Impact factor: 3.455

8.  Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances.

Authors:  Kirk J Brower; Brian E Perron
Journal:  Med Hypotheses       Date:  2009-11-11       Impact factor: 1.538

9.  Autism families with a high incidence of alcoholism.

Authors:  Judith H Miles; T Nicole Takahashi; Andrew Haber; Laura Hadden
Journal:  J Autism Dev Disord       Date:  2003-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.